Abiopharma

🔍 Xie Jian (Executive)

Company: Fulgent Genetics, Inc. (FLGT)

Report Date: 2025-09-03

Detailed Transactions and Holdings:

• Sold 1,128 shares of Common Stock at $22.0267 per share (Direct)
  Date: 2025-09-03 | Code: S | equity_swap_involved: false | shares_owned_after: 364,121.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-03 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 220,816.00 | Footnotes: F3

Footnotes:

• F1: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022.
• F2: The shares were sold in multiple transactions at prices ranging from $21.92 to $22.175, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
• F3: Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.